Crescendo Biologics is building a pipeline of novel, targeted T-cell enhancing Humabody® therapeutics based on its highly innovative VH antibody fragment platform through both in-house development and strategic partnerships. Crescendo’s proprietary VH technology produces human heavy chain-only antibodies in the transgenic Crescendo Mouse providing a unique source of fully human VH fragments that have matured in vivo to have high affinity, stability and solubility. VH fragments are the smallest antibody fragments that retain binding affinity and specificity offering the potential to generate novel products with improved drug-like properties and able to address unmet medical needs. Crescendo’s technologies originated from discoveries by scientists at the Babraham Institute, Cambridge (UK).
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.